Synergistic antitumor effect of a Î³-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma.

Yang, Xuran; Xia, Wei; Chen, Lin; Wu, Chuan Xing; Zhang, Cathy C; Olson, Peter; Wang, Xiao Qi

Yang, Xuran; Xia, Wei; Chen, Lin; Wu, Chuan Xing; Zhang, Cathy C; Olson, Peter; Wang, Xiao Qi.

Afiliación

Yang X; Department of Surgery, The University of Hong Kong, Hong Kong, China.
Xia W; Department of Surgery, The University of Hong Kong, Hong Kong, China.
Chen L; Department of Surgery, The University of Hong Kong, Hong Kong, China.
Wu CX; Department of Surgery, The University of Hong Kong, Hong Kong, China.
Zhang CC; Oncology Research Unit, Pfizer Global Research and Development, La Jolla, California, USA.
Olson P; Oncology Research Unit, Pfizer Global Research and Development, La Jolla, California, USA.
Wang XQ; Department of Surgery, The University of Hong Kong, Hong Kong, China.

Oncotarget ; 9(79): 34996-35007, 2018 Oct 09.

Article en En | MEDLINE | ID: mdl-30405889

Palabras clave

GSI; HCC; PF-03084014; antitumor; sorafenib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google